Clinical Trials Browser

Interventional × canakinumab × Clear all

NCT04239157 2026-05-20

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT06038526 2026-05-20

Evaluation of Canakinumab in High-Risk Former-Smokers

Phase 2 Active not recruiting

Lung Neoplasms

NCT05467800 2026-05-07

Study of Canakinumab in Patients With Myelofibrosis

Phase 2 Active not recruiting

Primary Myelofibrosis

NCT04789681 2026-04-16

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

Phase 2 Recruiting

Lung Neoplasms

NCT04028245 2026-04-15

SPARC-1

Phase EARLY_PHASE1 Completed

Carcinoma, Renal Cell

NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Phase 1 Active not recruiting

Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT03631199 2026-02-25

CANOPY-1

Phase 3 Terminated

673 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Phase 2 Recruiting

Classical hematology

Clonal Cytopenia of Undetermined Significance

NCT04905316 2025-06-17

CHORUS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03742349 2025-05-18

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Phase 1 Terminated

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04581343 2025-05-04

PanCAN-SR1

Phase 1 Completed

10 enrolled 26 charts

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT03447769 2024-10-09

Canopy-A

Phase 3 Terminated

1,382 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT03968419 2024-06-20

CANOPY-N

Phase 2 Terminated

88 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03484923 2024-06-18

PLATforM

Phase 2 Completed

196 enrolled 22 charts

Melanoma

NCT03626545 2023-08-21

CANOPY-2

Phase 3 Terminated

245 enrolled 29 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05725343 2023-02-13

CANAL

Phase 3 Terminated

Lung Neoplasms

NCT03064854 2022-08-15

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT02334748 2020-05-19

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Phase 3 Completed

31 enrolled 7 charts

Rheumatoid Arthritis, Systemic Juvenile, Bronchiolitis Obliterans Syndrome, Arthritis, Juvenile, Arthralgia, Mevalonate Kinase Deficiency, Cryopyrin-Associated Periodic Syndromes

NCT02911857 2018-08-20

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

Phase 3 Completed

4 enrolled 7 charts

Periodic Fevers Syndrome